A hidden immune backup system could supercharge mRNA cancer vaccines Scientists discovered a hidden backup system that could make future mRNA cancer vaccines even more powerful. - Date: - July 9, 2026 - Source: - WashU Medicine - Summary: - Researchers found that mRNA cancer vaccines can recruit an unexpected immune cell to launch powerful tumor-fighting responses, overturning a long-held assumption about how the vaccines work. The discovery could lead to more effective cancer vaccines and help scientists tailor treatments for better patient outcomes.

- Share: The success of mRNA vaccines against SARS-CoV-2 during the COVID-19 pandemic transformed vaccine science. Now, the same Nobel Prize winning technology is being adapted to fight cancer, with experimental mRNA vaccines already being tested against melanoma, small cell lung cancer, bladder cancer, and several other cancers. Researchers hope these vaccines could eventually provide powerful new ways to prevent and treat the disease.

A new study from Washington University School of Medicine in St. Louis has uncovered an unexpected feature of how these cancer vaccines work. In experiments with mice, scientists found that mRNA cancer vaccines remained highly effective even when an immune cell long believed to be essential was missing.

Instead, another closely related immune cell stepped in to trigger a strong attack against tumors. The findings, published in Nature, offer new insight into how the immune system responds to mRNA vaccines and could help researchers design more effective cancer vaccines in the future. "There is a lot of interest in applying the mRNA vaccine approaches used during the COVID-19 pandemic to the problem of inducing anti-tumor immunity," said senior author Kenneth M.

Murphy, MD, PhD, the Eugene Opie Centennial Professor of Pathology & Immunology at WashU Medicine. "By dissecting which immune cells are involved and how they coordinate the response, we're offering vaccine developers some additional mechanistic insights to consider in their goal of optimizing these vaccines against tumor proteins." Murphy also is a research member at Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine. How mRNA Cancer Vaccines Activate the Immune System mRNA vaccines deliver genetic instructions, known as messenger RNA, that tell immune cells to produce small pieces of protein.

Those protein fragments train the immune system to recognize and attack cells carrying the same proteins. For cancer vaccines, the proteins are chosen because they are unique to tumors, allowing immune cells to identify and destroy cancer cells while leaving healthy tissue largely unaffected. A group of immune cells called dendritic cells plays a central role in this process by producing the protein fragments from the mRNA instructions.

Another type of immune cell, known as T cells, then seeks out and destroys cells carrying those proteins. For years, researchers believed that one dendritic cell subtype called cDC1 was the primary driver of this response. While cDC1 is well known for preparing T cells to attack virus infected cells, scientists did not fully understand whether the same process occurred after mRNA vaccination against viruses or cancer.